Skip to main content

Biotech veteran Michael Gilman joins Arrakis full-time after $75M round

Waltham biotech startup Arrakis Therapeutics has grabbed the attention of Biogen veteran Michael Gilman full-time after raising a further $75 million.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.